Financials in USD. Standardized financial statements.
A compact view of how Indivior Pharmaceuticals Inc turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.24B | $1.19B | $1.09B | $901.00M | $791.00M | $647.00M | $785.00M | $959.92M | $1.15B | $968.89M |
| Revenue Growth? | +4.3% | +8.7% | +21.3% | +13.9% | +22.3% | -17.6% | -18.2% | -16.4% | +18.5% | 0.0% |
| Cost of Revenue? | $246.00M | $231.00M | $174.00M | $151.00M | $127.00M | $97.00M | $140.00M | $134.68M | $122.90M | $110.81M |
| Gross Profit? | $993.00M | $957.00M | $919.00M | $750.00M | $664.00M | $550.00M | $645.00M | $825.25M | $1.03B | $858.08M |
| Gross Margin? | +80.1% | +80.6% | +84.1% | +83.2% | +83.9% | +85.0% | +82.2% | +86.0% | +89.3% | +88.6% |
| Operating Expenses? | $728.00M | $925.00M | $1.07B | $831.00M | $451.00M | $706.00M | $467.00M | $508.14M | $601.89M | $520.16M |
| Operating Income? | $265.00M | $32.00M | -$156.00M | -$81.00M | $213.00M | -$156.00M | $178.00M | $317.11M | $423.32M | $337.92M |
| EBITDA? | $304.00M | $84.00M | -$99.00M | -$46.00M | $238.00M | -$123.00M | $230.00M | $310.42M | $436.97M | $149.27M |
| Income Before Tax | $239.00M | $14.00M | -$149.00M | -$89.00M | $190.00M | -$173.00M | $180.00M | $265.53M | $143.91M | $89.75M |
| Income Tax Expense | $29.00M | $11.00M | -$20.00M | -$44.00M | -$15.00M | -$25.00M | $46.00M | $2.87M | $82.98M | $57.69M |
| Net Income? | $210.00M | $2.00M | -$129.00M | -$44.00M | $205.00M | -$148.00M | $134.00M | $262.67M | $60.92M | $32.05M |
| EPS? | $1.68 | $0.02 | $0.01 | $-0.37 | $1.38 | $-1.08 | $0.95 | $1.81 | $0.42 | $0.22 |
| Diluted EPS? | $1.64 | $0.01 | $0.01 | $-0.37 | $1.31 | $-1.08 | $0.92 | $1.75 | $0.41 | $0.22 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality